Most studies of Low T3 syndrome (NTIS) routinely EXCLUDE thyroid patients. Sadly, our exclusion has become a research tradition.
In this post, I lay out the landscape and extent of our exclusion from this valuable area of thyroid hormone health research.
Everyone loses by our exclusion. Especially thyroid patients.
Everyone has something to gain from our inclusion. It can be a win-win.
We can move forward if we can show people the loss and the gain.
WHAT IS LOW T3 SYNDROME (NTIS) ABOUT?
NTIS is a syndrome that is characterized by an isolated low Free T3 while the TSH is not elevated above reference range. It often occurs during the process of a critical illness.
NTIS research focuses on the causes, processes and health outcomes of thyroid hormone metabolism imbalances that deplete T3 hormone. It examines the phases of NTIS in the settings of various diseases, how people recover from them, and what factors may contribute to higher or lower rates of death or poor recovery.
People with thyroid disease on thyroid therapy are very much at risk of Low Free T3.
Many of us experience chronic low T3 during therapy before illness and during chronic and critical illness. WE are the people this field should be studying the most!
What happens to us when WE get ill and our T3 stays low or goes lower ??
It just does not make any sense why we are excluded, over and over and over ….
THE MASSIVE SCALE OF OUR EXCLUSION
Here is an incomplete list of clinical studies on NTIS that EXCLUDED treated thyroid patients. Just scroll and notice the sheer number and range of health conditions!
- ZHANG ET AL, 2018 • Cardiac surgery in children
- SU ET AL 2018 • Surviving death after heart attack (acute MI)
- GAO ET AL 2018 • Chronic lymphocytic leukemia prognosis
- ATAOGLU ET AL 2018 • Cardiac, Kidney, Neurological disease & Cancer
- WANG ET AL 2018 • Disease severity in Chinese patients
- ZHAO ET AL 2017 • Post-stroke depression
- YAZICI ET AL 2017 • Acute coronary syndrome 1-year mortality
- YAN ET AL 2017 • Advanced chronic kidney disease
- WANG ET AL 2017 • Acute ischemic stroke
- ROTHBERGER ET AL 2017 • Acute heart failure
- QIU ET AL 2017 • Acute ischemia stroke
- JIANG ET AL 2017 • acute ischemic stroke
- GAO ET AL 2017 • Diffuse large B cell lymphoma
- ÇUHACI ET AL 2017 • Mortality in critically-ill patients
- BUNEVICIUS ET AL 2017 • Brain tumor 5-year survival
- ASFAR ET AL 2017 • Cardiovascular events in kidney disease
- XU ET AL 2016 • Acute Ischemic Stroke
- WANG ET AL 2016 • Idiopathic Dilated Cardiomyopathy
- PETRONE ET AL 2016 • Obstructive sleep apnea
- JANKAUSKIENE ET AL 2016 • LV mechanics post-myocardial infarction
- FAN ET AL 2016 • Radiation Enteritis
- RHEE ET AL 2015 • Cardiovascular risk factor in kidney disease
- QARI ET AL 2015 • Outcome of patients in critical care (ICU)
- KISHI 2015 • Risk in acute decompensated heart failure
- DIETRICH ET AL 2015 • Atrial remodeling in cardiac illness
- CHEN ET AL 2015 • Chronic heart failure & Type 2 diabetes
- ANASTASIOU ET AL 2015 • Acute liver failure
- KIM ET AL 2014 • ST-elevation myocardial infarction
- EDITA ET AL 2014 • Acute myocardial infarction
- CHUANG ET AL 2014 • Acute Heart Failure
- MEUWESE ET AL 2013-a • coronary calcification on dialysis
- WANG ET AL 2013 • acute ST-elevation myocardial infarction
- MEUWESE ET AL 2013-b • Cardiorenal syndrome
- BUNEVICIUS ET AL 2013 • Brain tumor surgery
- AGEWALL & TORNVALL 2013 • MI with normal coronary arteries
- MEUWESE ET AL 2012 • Maintenance hemodialysis
- KAYA ET AL 2012 • Coronary artery disease
- PAPPA ET AL 2011 • Non-critical illness
- PIMENTEL ET AL 2010 • Myocardial function impairment in heart failure
- PFISTER ET AL 2010 • NT-pro-BNP in cardiovascular patients
- IGLESIAS ET AL 2010 • Aged hospitalized patients after discharge
- GALLI ET AL 2010 • Pathophysiology of heart failure
- SONG ET AL 2010 • Stages of chronic kidney disease
- PINGITORE ET AL 2006 • Chronic heart failure
- PEETERS ET AL 2005 • Intensive care insulin treatment
- JAROSZYNSKI ET AL 2005 • ECG in hemodialyzed patients
- IERVASI ET AL 2003 • Heart disease mortality
- PAVLOU ET AL 2002 • Acute ischemic syndromes
- ASCHEIM & HYRNIEWICZ 2002 • Congestive heart failure
- FRIBERG ET AL 2001 • Acute MI (heart attack) mortality
- ASAKURA ET AL 2000 • Hyperemesis gravidarum (morning sickness)
- FEELDERS ET AL 1999 • Tumor necrosis factor alpha in cancer patients
- HEATH & LOUCKS 1994 • Athletic amenorrhea in exercising women
- LOUCKS & CALLISTER 1993 • Athletic amenorrhea in exercising women
- BELGOROSKY ET AL 1993 • Congenital heart disease surgery
- KAYIMA ET AL, 1992 • Chronic renal failure (kidney failure)
- KANO ET AL 1987 • Fulminant hepatitis
- FABER ET AL, 1987 • Hepatic coma, cancer, stroke, respiratory insufficiency
- KABADI 1986 • Metabolic control in diabetes
- BRENT & HERSHMAN, 1986 • Severe illness
- BRENT ET AL, 1986 • Severe illness
- DE MARINIS ET AL 1985 • Acute MI (heart attack)
- KABIDI & PREMACHANDRA 1984 • Type 2 diabetes
- KJELLMAN ET AL 1983 • Affective disorders
- BIANCHI ET AL 1983 • Critically ill patients
- BACCI ET AL, 1982 • Severely ill, hypothermia
- DAVIS ET AL, 1982 • End-stage renal disease
- KAPTEIN ET AL 1982 • Low T4 and Low T3
- KABADI ET AL 1982 • Diabetes, hyperglycemia
- DEMEESTER-MIRKINE ET AL 1981 • Elderly sick patients
- OLSEN, LAURBERG & WEEKE 1978 • Old age
- CHOPRA ET AL, 1975 • Liver cirrhosis, Kidney failure, Febrile illnesses
The list goes on…
I have so far found only THREE (3) articles on NTIS that examine the syndrome in treated thyroid patients. I’ll cover them in a separate post.
Basically, it’s unethical. All over the world, thyroid patients’ lives are affected by NTIS every day. We get sick and we lose T3, too.
Excluding us from NTIS resarch maintains apathy about thyroid patients’ suffering with lower T3 levels.
Excluding us perpetuates many myths about the insignificance of Low T3 during thyroid therapy. (See an earlier post where I debunk the myths)
Excluding us means that our T4-T3 conversion challenges, OUR hormone metabolic disorders and imbalances during thyroid therapy, do not get studied in the context of their effects on our overall health.
Excluding us from NTIS research blinds people to the health outcomes of thyroid therapy approaches that fail to optimize Free T3 levels, and approaches that are more successful.
WHAT THYROID PATIENTS LOSE
As we continue to be excluded:
- Doctors continue believing that our health is not at risk from our low(er) T3. They are often falsely reassured that our thyroid therapy protects us during illness and low T3 is temporary.
- We have difficulty protecting our access to routine Free T3 testing to optimize our levels for our health and quality of life
- We lack a key rationale for RT3 testing. This subfield of research has relied on RT3 testing more than any other.
- We lack scientific backing to advocate for individually customized doses of T3 in our therapy for health reasons.
WHAT EVERYONE GAINS
Including us in NTIS research is a huge step toward the T3-paradigm shift we all need.
It puts focus on the power of T3 hormone over human health.
It shows that T3 sufficiency vs. T3 depletion can make the difference between health and illness, life and death.
It takes the focus off of TSH for a change. The obsession with this hormone has blinded many to the independent health effects of thyroid hormone levels and ratios regardless of where TSH falls.
WE are the kind of research participants this area of thyroid science needs.
Our inclusion will include the missing variables of thyroid disease, thyroid loss and thyroid therapy types.
It is the path of innovation and exploration. This research tradition took an innovative path early in its development. It is multidisciplinary. NTIS is studied not only by thyroid scientists, but by experts in other disease areas, primarily cardiology and kidney disease. They want to understand how thyroid hormones influence illness in their area of specialization.
Currently, NTIS research is very fearful and reluctant to trial T3 thyroid therapies. We are already in need of thyroid therapy. Researchers don’t need to be as fearful of interfering with nature by exploring our T3 therapy options as we encounter T3 loss in critical and chronic illness.
Innovation in T3-based thyroid therapy in the context of NTIS can move our combination therapy trials past unscientific restrictions on tiny doses of T3 at a fixed ratio alongside T4 (these trials dose with fixed ratios of T3:T4 based on a statistical average found among 14 iodine-overdosed people in a study by Pilo et al, 1990).
If we are included, medicine will further understand thyroid hormone metabolism dysfunction in all humans.
A thyroid patients campaign that focuses on the T3 hormone fights for every human being, not just for people with thyroid disease.
Everyone needs T3 sufficiency for life.
Everyone can be at risk of T3 depletion, even the thyroid-healthy.
The T3 hormone does indeed hold keys to health and illness, life and death.
Including thyroid patients on therapy in NTIS research is that important, folks!
THE EXCITING FRONTIERS OF RESEARCH
Including thyroid patients in NTIS research means you, dear research scientist, can explore key questions that nobody else is studying:
- Are certain kinds of thyroid patients more susceptible to NTIS?
- Are certain kinds of thyroid patients more at risk of dying or not recovering from NTIS?
- Can thyroid therapy itself induce the metabolic imbalances of NTIS even without an illness as trigger?
- How does the process of recovery from NTIS happen without a TSH-stimulated thyroid gland? Can thyroid patients recover?
- Which approach to thyroid therapy supports recovery from NTIS better than another?
WHAT CAN WE DO AS THYROID PATIENTS?
Speak out to researchers about the ethical injustice of our exclusion.
Tell them why it’s wrong to exclude us, and the benefits of including us.
Canadian groups we can address in our self-advocacy:
- Researchers in the Canadian Society for Endocrinology and Metabolism (CSEM),
- Medical research funding organizations like Canadian Institute for Health Research (CIHR) that select research projects to fund
- Canada’s Tri-Council Research Ethics Panel, which is charged with educating researchers on ethical conduct in research and protecting the human rights of research participants
Our health and safety on therapy needs to be studied NOW, before we get sick and while we are suffering.
Continue your path of lifelong learning and develop your health advocacy skills:
- Keep becoming scientifically informed about “Low(er) T3” causes. It can help build mutual respect in dialogue with your doctors. You can gain self-confidence to advocate for yourself and your peers.
- Keep learning how thyroid hormones affect your symptoms and risks in other areas of health.
- Use this body of research to advocate for your own Free T3 & Free T4 testing, RT3 testing, and customized thyroid therapy.
- Keep following the Campaign’s posts and sharing dialogue in online patient groups. Let’s learn together the ways we can move thyroid therapy forward.